Eosinophilic esophagitis (EoE) is a chronic inflammatory disease that encompasses esophageal symptoms along with eosinophilic infiltration of the esophageal epithelium. EoE is an evolving disease that has been a subject of interest to many researchers since the first studies recognized this condition as a new and distinct clinicopathological entity 25 years ago. Clinical presentation in adult patients may include dysphagia, food impaction, vomiting, and reflux symptoms. The diagnosis of EoE is based on the combination of clinical history suggestive of esophageal dysfunction, endoscopic features indicative of the disease, and histology revealing eosinophilic infiltration of the esophageal epithelium that persists after a trial of proton pump inhibitor therapy along with the exclusion of other disorders that may be associated with esophageal tissue eosinophilia. The interplay between EoE and gastroesophageal reflux disease (GERD) is complex, and differentiating these two conditions continues to be difficult and challenging in clinical practice. The mainstay treatment includes dietary modification, topical steroids, and/or endoscopic dilation. The primary care physician (PCP) plays an important role in improving patient care and quality of life by ensuring early referral and participating in management and follow-up. This article provides an overview of the current knowledge base regarding the disease including epidemiology, genetics, pathogenesis, common clinical presentations, the interplay between EoE and GERD, diagnostic approaches, and therapeutic options available to the PCP.
INTRODUCTION
Over the past 20 years, eosinophilic esophagitis (EoE) has dramatically emerged as a prevalent cause of gastrointestinal morbidity in adults.
Classically, EoE has been defined as a chronic immune/antigen-mediated inflammatory condition of the esophagus, characterized clinically by esophageal symptoms of dysphagia and food impaction, and histologically by eosinophil-predominant inflammation (presence of ≥15 eosinophils/high-power field in at least one esophageal biopsy), both of which are nonresponsive to prolonged acid suppression with proton pump inhibitors (PPIs). 1) Additionally, the exclusion of systemic and local causes of esophageal eosinophilia is mandatory for diagnosis ( Table 1 ). 1) Since 2011, the most significant development in the definition of EoE has been linked to the growing concept of a distinct disease phenotype termed PPI-responsive esophageal eosinophilia (PPI-REE). 1) This phenotype describes patients with clinical, endoscopic, and histological features of EoE, all of which totally resolve on PPI therapy but are not necessarily associated with gastroesophageal reflux disease (GERD). 2) First described by Paul Ehrlich in 1879, the eosinophil is a non-specific inflammatory cell. 3) Hence, eosinophilic infiltration may be a common finding in numerous inflammatory and immunological conditions. In the 1980s, multiple case reports were published describing an eosinophilic infiltration of the esophagus-a tissue normally devoid of eosinophils-among patients experiencing symptoms of dysphagia, reflux disease, and other esophageal symptoms. [4] [5] [6] [7] However, Attwood et al. 8) were the first to publish an article in 1993, titled "Esophageal eosinophilia with dysphagia, a distinct clinico-pathologic syndrome. " In their case series, the authors described 12 adult-predominantly male-patients with dysphagia who exhibited a high concentration of intra-epithelial eosinophils in esophageal biopsies, normal endoscopy, and normal 24-hour esophageal pH monitoring, exhibiting a distinctive clinicopathological syndrome not previously described. This article alerted clinicians to a new syndrome affecting mainly young male patients with an allergic background who present with dysphagia and food impaction. In the past two decades, EoE has been extensively investigated around the world, paralleling the in-creasing incidence and prevalence of the disease. In the current review, we provide a concise, up-to-date summary of the disease, along with practical guidance for primary care physicians (PCPs) regarding diagnosis and management of patients with EoE.
EPIDEMIOLOGY
EoE is more common in Caucasian populations, with a male to female ratio of 3:1. 9) The prevalence is also increasing among African-American, Hispanic, and Asian populations, and is currently as high as 50
cases per 100,000 in the western population. Current incidence rates of EoE range between 6 and 13 new cases per 100,000 population per year in Europe, the United States, and Canada. [10] [11] [12] [13] Although EoE can affect all age groups, most cases occur in children and in adults aged 30-50 years. 12, 13) A Japanese study aimed to determine the prevalence 14) Individuals with EoE usually experience other concomitant atopic/ allergic conditions including allergic rhinitis, bronchial asthma, food allergies, and eczema. 15) 
GENETICS
EoE has a strong familial association and 8% of parents of an EoE child have also been diagnosed with the disease. Additionally, siblings of EoE patients have 80 times the risk for developing the disease compared with the general population. In vitro studies have shown esophageal epithelial cells of EoE patients to have mutations in the filaggrin gene, which binds to keratin in epithelial cells and is central to barrier integrity in these cells. 16) Other studies have revealed genomic defects on chromosome 5q22, which is involved in T-helper cell 2 (Th2)-mediated cytokine pathways. 17) Later investigations using genome-wide association studies have demonstrated linkages with variants at the c11orf30 locus, STAT6 gene (allergic sensitization and serum immunoglobulin E [IgE]), and CAPN14 (calcium-regulated protease). [18] [19] [20] Ongoing research will better define the role of genetic inheritance and its contribution to the familial pattern observed in this evolving disease.
PATHOGENESIS
EoE may appear in genetically predisposed individuals after exposure of the esophagus to specific foods and aeroallergens, even though the exact mechanism remains unclear. 21) EoE is believed to be a multifactorial disease; environmental factors, food allergens, acid exposure, and genetic factors play a role in the pathogenesis of this disease. Normally, the esophagus is not infiltrated by eosinophils. However, in EoE, they accumulate in the esophageal mucosa through Th2-and IgE-mediated pathways, resembling the response observed in food allergies and GERD. This response model was validated in a previous study that demonstrated that only T cell-deficient-not B cell-deficient-mice were unable to develop EoE. 22) In the past, it was believed that adult-onset disease was caused by aero-allergens, while childhood disease was mainly secondary to food allergies. 23) Currently, it is firmly established that food allergies play a major role in the development of EoE both in adults and children. 24, 25) Milk, wheat, soy, egg, peanuts, rye, beef, and beans are considered to be the most common food allergens. In the meantime, it has been shown that both groups are sensitized to aero-allergens, indicating their possible involvement in disease pathogenesis. 26) Esophageal epithelial cells exposed to acid(s) may result in enhanced permeability to potential allergens, which in turn may further contribute to the inflammatory cascade. 27) The release of eosinophil and mast cell products at the end of Th2mediated pathways leads to stimulation and regulation of inflammation and remodeling in the esophagus, mainly through profibrotic and proangiogenic factors. Subsequently, this process explains the main histological features of EoE-like subepithelial fibrosis and esophageal thickening, which in turn lead to characteristic endoscopic findings and the typical clinical manifestations of dysphagia and food impaction. 28) 
CLINICAL PRESENTATION
Typical presenting symptoms depend on age at presentation. The major symptoms in adults include esophageal dysphagia with solids (reported in 70% of cases) and food impaction, which necessitates endoscopic removal and usually leads to the diagnosis. 29, 30) Other less typical symptoms in adults with EoE include abdominal pain, vomiting, chest pain, heartburn, and regurgitation. In children and infants, the most prevalent symptoms include reflux-like symptoms, vomiting, abdominal pain, food refusal, and failure to thrive. 31) A study by Lynch et al. 32) revealed that men generally present with typical symptoms, while women present with symptoms that mimic GERD. Because aeroallergens play a significant role in pathogenesis, EoE is diagnosed more commonly during the spring and summer, consistent with high counts of environmental pollens (grass, trees, and weeds). 33) 
ROLE OF THE PRIMARY CARE PHYSICIAN IN THE DIAGNOSIS OF EOSINOPHILIC ESOPHAGITI
The PCP is generally the first-contact health care provider for patients with suspected EoE; hence, awareness and vigilance of the PCP are crucial in identifying clinical features and symptoms suggestive of the disease and referring patients to appropriate work-up. The major "suggestive signs" of EoE are listed in Table 2 
DIAGNOSIS
The initial diagnostic step in patients presenting with dysphagia, reflux-like symptoms non-responsive to PPI therapy, or any other symptoms suggestive of EoE is esophagogastroduodenoscopy, with multiple esophageal biopsies. 1, 38) The five major endoscopic features of EoE-according to the EoE endoscopic reference score-include esophageal mucosal edema, ring formation, white exudates, furrows, and fibrotic strictures. 39, 40) Additional endoscopic features include mucosal fragility, so called "crepe paper, " and a narrow-caliber esophagus. 38, 39) A meta-analysis of 4,678 EoE patients by Kim et al. 41) aimed to define the prevalence and the diagnostic utility of these endoscopic findings in the diagnosis of EoE. Typical endoscopic findings were observed in 83% of patients with EoE. The pooled sensitivity of these findings was low (15%-48%), while the specificity was >90%. 41) Therefore, typical endoscopic findings play an important role in the diagnosis of EoE, but they may not be present in all patients and the diagnosis of EoE cannot be established based on their presence. Endoscopist awareness is important while scoping a patient with suspected disease. 42) Esophageal histology revealing pathological eosinophilic infiltration is the gold standard for diagnosing EoE. According to the most recent guidelines published in 2017, it is recommended that at least six biop-sies be obtained from the distal and proximal parts of the esophagus as well as from areas of endoscopic abnormality, mainly white exudates and longitudinal furrows. 42) It is also recommended to obtain samples from the duodenal and gastric mucosal biopsies to exclude eosinophilic gastroenteritis. 42) The accepted threshold for eosinophil density for the diagnosis of EoE is 15 eosinophils/high-power field (standard size, 0.3 mm 2 ) in the esophageal mucosa, taken as the peak concentration in the specimens examined. 43, 44) Additional histological findings include eosinophil abscesses, stromal fibrosis, dilated intercellular spaces, basal zone hyperplasia, and papillary elongation of squamous cells. 45) To confirm the diagnosis of EoE, eosinophilic infiltration should be isolated to the esophagus, persist after 8 weeks of twice-daily PPI treatment, and the exclusion of other causes of eosinophilia ( Figure 1 ). 43, 46) 
NON-INVASIVE BIOMARKERS: ANY ROLE IN DIAGNOSING EOSINOPHILIC ESOPHAGITIS?
Although its diagnostic accuracy is very low, serum eosinophil level has consistently been shown to correlate with the degree of esophageal eosinophilia and decrease after histological remission of the disease. [47] [48] [49] [50] [51] Nevertheless, serum eosinophil count currently has no role in diagnosing or monitoring EoE. Several biomarkers, including serum IgE, eosinophil cationic protein, eosinophil-derived neurotoxin, and various chemokines, have failed to demonstrate any utility in diagnosing or monitoring the disease. 52, 53) 
MANAGEMENT
The primary aim of treatment is to improve patient symptoms and quality of life, as well as to prevent esophageal structural and functional complications. Active EoE interferes with food intake and is associated with symptoms of dysphagia, food impaction, and impaired quality of life. 54) Chronic inflammation leads to esophageal tissue remodeling and stricture(s) formation, which results in decreased esophageal compliance and increased stiffness, subsequently inducing symptoms of dysphagia and food impaction. 55) Long-term treatment studies with topical steroids have shown that remodeling can be prevented or reversed with therapy. 56 
PHARMACOLOGICAL THERAPY
Oral topical corticosteroids have become the first-line medical therapy in adult patients. 57) The efficacy of topical steroids for histological remission has been confirmed in several randomized trials. Fluticasone propionate inhaler (880 μg) puffed directly into the mouth and then dry swallowed twice per day for 6-8 weeks has been proven to be effective in reducing symptoms and EoE. [58] [59] [60] [61] [62] [63] [64] Patients are advised to avoid food or drink for 30 minutes to prevent rinsing the medication from the esophageal mucosa. Oral viscous budesonide (OVB) has been shown to have a longer contact time with the esophageal mucosa due to its high viscosity. OVB (1 mg) twice per day for 8 weeks has been shown to decrease esophageal symptoms and reduce EoE. 48) Because only 1% of the topical steroid is absorbed, systemic side effects are extremely rare, although oral and esophageal candidiasis can occur in 5%-26% of patients. 48, 64) Systemic corticosteroids are effective drugs for inducing clinical and histological remission in patients with EoE; however, they are not recommended as a first-line pharmacological therapy due to the high rate of systemic side effects. 42, 46) In case of topical steroid failure, prolonged or higher doses of topical steroids, systemic steroids, dietary modification, or esophageal dilation should be attempted to achieve symptomatic improvement (Figure 1) . 42, 46) 
EMERGING DRUGS
The efficacy and safety of several new drugs are currently being investigated for the treatment of EoE. In a previous case series, immunomodulators (azathioprine and 6 mercaptopurine) induced and maintained clinical and histological remission in patients with steroid-dependent EoE. 65) A mast cell stabilizer, cromolyn sodium, demonstrated negative results in EoE patients. 66) Montelukast, which is an eosinophil-stabilizing agent, has been shown to improve clinical symptoms but without histological improvement. 67) Biological treatment, antiinterleukin 5, and interleukin-13 antibodies have been shown to reduce eosinophilia but with very mild symptomatic improvement. [68] [69] [70] Nevertheless, randomized controlled trials aimed at better defining the efficacy and safety of these novel emerging drugs and to determine their role in treatment strategies for EoE, are warranted.
DIETARY MODIFICATION
Dietary modification is considered to be an effective treatment option for EoE. Most research investigating dietary treatments for EoE have been conducted in pediatric populations; therefore, there are less data 
ENDOSCOPIC THERAPY
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